KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.

Neal D Shore, Thomas B Powles, Jens Bedke, Matthew D Galsky, Joan Palou Redorta, Ja Hyeon Ku, Michal Kretkowski, Evanguelos Xylinas, Boris Alekseev, Dingwei Ye, Félix Guerrero-Ramos, Alberto Briganti, Girish S Kulkarni, Julia Brinkmann, Anna-Maria Calella, Rossano Cesari, Anthony Eccleston, Elisabete Michelon, Jennifer Vermette, Caimiao Wei, Gary D Steinberg

Nat Med 31(8) 2806-2814

PMID40450141
PMCIDPMC12353837
DOI10.1038/s41591-025-03738-z
发表日期2025-05-31
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Bacillus Calmette-Guérin (BCG) induction and maintenance (I+M) after transurethral resection of bladder tumor is standard of care (SOC) in high-risk non-muscle invasive bladder cancer (NMIBC). However, disease recurrence/progression occurs in approximately 40% of patients at 2 years, with unfavorable prognosis. Limited bladder-sparing therapeutic options exist, and no improvements to response durability have been observed in decades. CREST is a global, phase 3, randomized trial evaluating subcutaneous sasanlimab in combination with BCG-I+M (Arm A), sasanlimab in combination with BCG-I (Arm B) or BCG-I+M (Arm C) in BCG-naive high-risk NMIBC. The primary endpoint was investigator-assessed event-free survival (EFS) for Arm A versus Arm C; key secondary endpoints were EFS (Arm B versus Arm C) and overall survival. Patients were randomized 1:1:1 to Arm A (N = 352), Arm B (N = 352) and Arm C (N = 351). The trial met its primary endpoint with a statistically significant and clinically meaningful prolongation of EFS (Arm A versus Arm C); hazard ratio, 0.68 (95% confidence interval: 0.49-0.94); one-sided P = 0.0095. The 36-month estimated EFS rates were 82.1% (Arm A) and 74.8% (Arm C). EFS benefit for Arm A versus Arm C was observed across prespecified subgroups, including carcinoma in situ (CIS) and T1. The safety profile of the combination was consistent with the known profiles. To our knowledge, sasanlimab is the first anti-PD-1 antibody to show a clinically meaningful prolongation of EFS when combined with BCG-I+M versus SOC in patients with BCG-naive high-risk NMIBC. Sasanlimab combined with BCG-I+M has the potential to redefine the treatment paradigm and clinical decision-making for patients with BCG-naive high-risk NMIBC. ClinicalTrials.gov identifier: NCT04165317 .

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Analysis of EFS in the intent-to-treat population for sasanlimab + BCG-I+M versus BCG-I+M and sasanlimab + BCG-I versus BCG-I+M. For EFS, an event was defined as the first of recurrence of high-grade disease, progression of disease, persistence of CIS (for patients with CIS at randomization) or death due to any cause. a , Kaplan–Meier estimates of EFS for sasanlimab + BCG-I+M versus BCG-I+M according to treatment arm in the intent-to-treat population. The dashed lines indicate EFS at 24 months and 36 months. b , Kaplan–Meier estimates of EFS for sasanlimab + BCG-I versus BCG-I+M according to treatment arm in the intent-to-treat population. The dashed lines indicate EFS at 24 months and 36 months.

A

Event-free survival

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme upward reversal
查看结果
B

Event-free survival

Fig. 2 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:off origin start
查看结果
KM Figure2 个面板

Fig. 4

Analysis of OS in the intent-to-treat population. a , Kaplan–Meier estimates of OS for sasanlimab + BCG-I+M versus BCG-I+M. b , Kaplan–Meier estimates of OS for sasanlimab + BCG-I versus BCG-I+M.

A

OS

Fig. 4 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:off origin start
查看结果
B

OS

Fig. 4 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:off origin start
查看结果
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1CONSORT diagram. a The first patient was randomized on 20 January 2020, and the last patient was randomized on 16 November 2021. b One patient was a screen failure but was randomized in error. c Two patients withdrew from study treatment in the sasanlimab + BCG-I arm due to recurrence of low-grade disease. d Lack of efficacy refers to patients who experience an EFS event of recurrence of high-grade disease, persistence of CIS or progression of disease. CRF, case report form.
非 KM Figure
Fig. 3Forest plot of the analyses of EFS in prespecified subgroups for sasanlimab + BCG-I+M versus BCG-I+M. The HR for EFS in all patients was calculated on the basis of an analysis stratified by the presence of CIS at randomization (yes or no) and geography (United States, Western Europe and Canada or rest of world). In each subgroup, the HR for EFS was estimated with the use of unstratified Cox proportional hazards models. Data are presented as HR (center) with 95% CIs (error bars).
非 KM Figure
Extended Data Fig. 1Analysis of event-free survival in the patients with carcinoma in situ at randomization (with or without papillary tumors) for sasanlimab + BCG-I+M vs BCG-I+M. For EFS, an event was defined as the first of recurrence of high-grade disease, progression of disease, persistence of CIS (for patients with CIS at randomization), or death due to any cause. Kaplan-Meier estimates of EFS according to treatment arm. The dashed line indicates EFS at 36 months. BCG-I+M, induction and maintenance regimen of intravesical Bacillus Calmette-Guérin; CIS, carcinoma in situ; EFS, event-free survival.
非 KM Figure
Extended Data Fig. 2Analysis of event-free survival in the patients with T1 tumor (with or without carcinoma in situ) for sasanlimab + BCG-I+M vs BCG-I+M. For EFS, an event was defined as the first of recurrence of high-grade disease, progression of disease, persistence of CIS (for patients with CIS at randomization), or death due to any cause. Kaplan-Meier estimates of EFS according to treatment arm. The dashed line indicates EFS at 36 months. BCG-I, Bacillus Calmette-Guérin induction regimen of intravesical Bacillus Calmette-Guérin; BCG-I+M, induction and maintenance regimen of intravesical Bacillus Calmette-Guérin; CIS, carcinoma in situ; EFS, event-free survival.
非 KM Figure
Extended Data Fig. 3Forest plot of the analysis of event-free survival in prespecified subgroups for sasanlimab + BCG-I vs BCG-I+M. The hazard ratio for EFS in all patients was calculated on the basis of an analysis stratified by the presence of carcinoma in situ at randomization (yes or no) and geography (US, Western Europe and Canada, or rest of world). In each subgroup, the hazard ratio for EFS was estimated with the use of unstratified Cox proportional-hazards models. Data are presented as hazard ratio (center) with 95% confidence intervals (error bars). BCG-I+M, induction and maintenance regimen of intravesical Bacillus Calmette-Guérin; CIS, carcinoma in situ; CRF, case report form; EFS, event-free survival.
非 KM Figure
Extended Data Fig. 4Probability of remaining in Complete Response for patients with CIS at randomization who achieved Complete Response for sasanlimab + BCG-I+M vs BCG-I+M. Kaplan-Meier estimates for duration of complete response for sasanlimab + BCG-I+M vs BCG-I+M in for patients with CIS at randomization who achieved CR. The dashed lines indicate the probability of remaining in complete response at 12, 24 and 36 months. BCG-I+M, induction and maintenance regimen of intravesical Bacillus Calmette-Guérin; CIS, carcinoma in situ.
非 KM Figure
Extended Data Fig. 5Plot of mean change from baseline over time for EORTC QLQ-C30 global health status by visit. BCG-I+M, induction and maintenance regimen of intravesical Bacillus Calmette-Guérin; C, cycle; D, day.
非 KM Figure